GUEST EDITORIAL An Inflection Point for Retinal Therapy

PentaVision is an independent company dedicated to eye care professionals. More about our magazines, newsletters, conferences, education and other services at pentavisionmedia.com.

Share

The field of retina has seen advancements in drug delivery systems, particularly the recent approval of Xipere for suprachoroidal drug delivery, marking a potential inflection point. This special edition of Retinal Physician intends to explore the benefits, experience, and future avenues of suprachoroidal delivery, particularly in the context of noninfectious uveitic macular edema, gene therapy, and the treatment of melanoma.

Original Source(s)

GUEST EDITORIAL An Inflection Point for Retinal Therapy

PentaVision is an independent company dedicated to eye care professionals. More about our magazines, newsletters, conferences, education and other services at pentavisionmedia.com.

  • by Mark R. Barakat, MD

  • August 1, 2022

  • 4 min

Related Content

Can Diabetic Eye Testing Be Simplified?

Three-test models matched nine-test battery in classifying disease stages

Retinal AI Predicts Neonatal Lung Disease

Retinal scans already performed in the NICU could flag infants at risk for serious lung disease before standard diagnosis

Understanding Protocol AO, the DRCR Retina Network’s Study of Home OCT

A conversation with Christina Y. Weng, MD, MBA